Study guide

10.2 Pediatric Sickle Cell Vaso-occlusive Crises, Thalassemia & ITP

Saudi Medical Licensing Examination SMLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Overview & Foundation of Clinical Practice

1.1 Exam Format, Blueprint & Preparation Strategy 1.2 Medical Bioethics, Patient Safety & SCFHS Regulations 1.3 Biostatistics & Clinical Epidemiology in Saudi Healthcare

2 Chapter 2: Internal Medicine - Cardiovascular & Respiratory Systems

2.1 Coronary Artery Disease, Dysrhythmias & Heart Failure 2.2 Respiratory Failure, Asthma, COPD & Infiltrative Lung Diseases 2.3 Critical Care Medicine, Shock Syndromes & Mechanical Ventilation

3 Chapter 3: Internal Medicine - Gastroenterology, Renal & Endocrine Systems

3.1 Hepatobiliary Disorders, Peptic Ulcers & Inflammatory Bowel Disease 3.2 Acute Kidney Injury, Chronic Kidney Disease & Electrolyte Imbalances 3.3 Diabetes Mellitus, Thyroid Disorders & Adrenal Axis Pathologies

4 Chapter 4: Internal Medicine - Infectious Diseases, Hematology & Subspecialties

4.1 Saudi Regional Infections (MERS-CoV, Brucellosis, TB, Dengue) & Antimicrobial Therapy 4.2 Hemoglobinopathies (Sickle Cell & Thalassemia), Anemias & Hematologic Malignancies 4.3 Connective Tissue Diseases, Stroke, Epilepsy & Movement Disorders 4.4 Psychiatry, Geriatrics & Behavioral Health

5 Chapter 5: Obstetrics - Antepartum & Intrapartum Care

5.1 Routine Prenatal Care, Screening & Fetal Assessment 5.2 Placental Disorders, Bleeding in Pregnancy & Isoimmunization 5.3 Normal Labor, Malpresentation, Operative Delivery & Fetal Monitoring

6 Chapter 6: Obstetrics - High-Risk Complications & Postpartum Care

6.1 Preeclampsia, Eclampsia & HELLP Syndrome 6.2 Preterm Labor, Premature Rupture of Membranes & Cervical Insufficiency 6.3 Postpartum Hemorrhage, Puerperal Infections & Maternal Mortality

7 Chapter 7: Gynecology & Reproductive Health

7.1 Menstrual Disorders, Endometriosis & Fibroids 7.2 Infertility Workup, Contraception & Menopause 7.3 Cervical, Uterine & Ovarian Neoplasms

8 Chapter 8: General Pediatrics, Neonatology & Development

8.1 Developmental Milestones, Growth Charts & Failure to Thrive 8.2 Saudi National Immunization Schedule & Well-Child Care 8.3 Neonatal Resuscitation, Jaundice, Respiratory Distress & Prematurity

9 Chapter 9: Pediatric Medicine - Respiratory, Cardiac & GI

9.1 Croup, Epiglottitis, Bronchiolitis, Asthma & Cystic Fibrosis 9.2 Congenital Heart Disease (Cyanotic & Acyanotic) & Rheumatic Fever 9.3 Dehydration, Gastroenteritis, Intussusception & Pyloric Stenosis

10 Chapter 10: Pediatric Medicine - Infections, Hematology, Emergencies & Subspecialty Systems

10.1 Exanthems, Meningitis, Sepsis & Febrile Seizures 10.2 Pediatric Sickle Cell Vaso-occlusive Crises, Thalassemia & ITP 10.3 Pediatric Trauma, Ingestion, Poisoning & Child Abuse Recognition 10.4 Pediatric Neurology, Nephrology & Musculoskeletal Disorders

11 Chapter 11: General Surgery & Surgical Principles

11.1 Preoperative Risk Assessment, Wound Healing & Surgical Infections 11.2 Fluid Resuscitation, Acid-Base Disturbances & Surgical Shock 11.3 Acute Abdomen, Appendicitis, Hernias, Gallbladder & Colorectal Surgery

12 Chapter 12: Trauma, Critical Care & Surgical Emergencies

12.1 ATLS Primary/Secondary Survey, Thoracic & Abdominal Trauma 12.2 Thermal/Chemical Burns, Parkland Formula & Wound Management 12.3 Breast Masses, Thyroid Nodule Evaluation & Surgical Oncology

13 Chapter 13: Surgical Subspecialties

13.1 Nephrolithiasis, BPH, Prostate Cancer & Increased Intracranial Pressure 13.2 Common Fractures, Compartment Syndrome & Pediatric Orthopedics 13.3 Epistaxis, Red Eye Emergencies, Peripheral Vascular Disease & Aortic Aneurysms

10.2 Pediatric Sickle Cell Vaso-occlusive Crises, Thalassemia & ITP

Key Takeaways Explain This Topic AI

Sickle Cell Disease is highly prevalent in the Eastern and Southern provinces of Saudi Arabia; the pre-marital screening program mandates testing for hemoglobinopathies.

Vaso-occlusive crises (VOC) are managed with aggressive hydration, multimodal analgesia (including opioids), and identification of precipitating factors like infection.

Acute chest syndrome is a life-threatening complication of SCD characterized by new pulmonary infiltrates, fever, and hypoxia, often necessitating broad-spectrum antibiotics and exchange transfusion.

Beta-thalassemia major presents at 6 months of age with severe anemia and requires lifelong transfusions and iron chelation therapy to prevent iron overload complications.

Immune Thrombocytopenia (ITP) usually follows a viral illness; children with isolated thrombocytopenia and no bleeding can often be observed without pharmacological intervention.

Last updated: July 2026

Pediatric Hematology: Sickle Cell Disease, Thalassemia & ITP

Hematological disorders are of paramount importance in Saudi Arabia due to the high prevalence of inherited hemoglobinopathies, particularly in the Eastern and Southern provinces. The Saudi Ministry of Health mandates a pre-marital screening program to identify carriers of Sickle Cell trait and Thalassemia trait, significantly impacting the epidemiology and public health approach to these conditions.

1. Sickle Cell Disease (SCD)

Sickle cell disease is an autosomal recessive hemoglobinopathy caused by a point mutation (valine substituted for glutamic acid at the 6th position of the beta-globin chain), leading to the production of Hemoglobin S (HbS). Under hypoxic, acidotic, or dehydrating conditions, HbS polymerizes, causing red blood cells to sickle. This leads to hemolysis and vaso-occlusion.

Acute Complications and Management

Vaso-Occlusive Crisis (VOC): VOC is the most common reason for emergency visits in SCD. It typically presents as severe bone pain (e.g., dactylitis in infants, long bone/back pain in older children). Management:

Hydration: IV fluids (usually 1.5 times maintenance) to decrease blood viscosity.

Analgesia: Aggressive multimodal pain control. NSAIDs (e.g., ibuprofen, ketorolac) for mild/moderate pain; IV opioids (e.g., morphine, fentanyl) for severe pain. Meperidine is avoided due to the risk of seizure-inducing metabolites.

Oxygen: Only if the patient is hypoxic (SpO2 < 92%).

Acute Chest Syndrome (ACS): ACS is a leading cause of mortality in SCD. It is defined by a new pulmonary infiltrate on chest X-ray combined with fever, chest pain, tachypnea, or hypoxia. It can be triggered by infection (e.g., Mycoplasma , Chlamydia , S. pneumoniae ), fat embolism from bone marrow infarction, or hypoventilation. Management:

Broad-spectrum antibiotics (a macrolide plus a 3rd-generation cephalosporin).

Bronchodilators if wheezing is present.

Incentive spirometry to prevent atelectasis.

Blood transfusion (simple or exchange transfusion) to lower the HbS percentage and improve oxygen delivery.

Splenic Sequestration Crisis: Seen primarily in young children (usually <5 years) whose spleens have not yet auto-infarcted. It involves rapid pooling of blood in the spleen, leading to acute severe anemia, profound reticulocytosis, splenomegaly, and hypovolemic shock. Management: Immediate volume resuscitation and packed red blood cell (PRBC) transfusion. Splenectomy is often required after recovery to prevent recurrence.

Infection Risk: Due to functional asplenia by early childhood, SCD patients are highly susceptible to encapsulated organisms ( S. pneumoniae , H. influenzae , N. meningitidis ). Prophylactic daily penicillin V is administered starting at 2 months of age and continued at least until age 5. Any fever >38.5°C in an SCD patient requires prompt evaluation, blood cultures, and empiric parenteral antibiotics (e.g., Ceftriaxone).

2. Thalassemia

Thalassemias are quantitative defects in the production of globin chains (alpha or beta), resulting in ineffective erythropoiesis, hemolysis, and microcytic, hypochromic anemia.

Beta-Thalassemia Major (Cooley's Anemia)

Patients are usually asymptomatic at birth due to the protective effect of fetal hemoglobin (HbF). Symptoms begin around 6 months of age as HbF declines and is replaced by defective HbA. Clinical Presentation: Severe anemia, failure to thrive, hepatosplenomegaly, and skeletal changes due to extramedullary hematopoiesis (e.g., frontal bossing, maxillary overgrowth giving a "chipmunk facies", and "hair-on-end" appearance on skull X-ray). Diagnosis: Hemoglobin electrophoresis confirms the diagnosis (absence or near absence of HbA, markedly elevated HbF, and variable HbA2). Management:

Lifelong regular blood transfusions to maintain Hb > 9 g/dL and suppress ineffective erythropoiesis.

Iron Chelation Therapy: Essential to prevent iron overload, which can lead to restrictive cardiomyopathy, endocrinopathies, and liver cirrhosis. Deferasirox (oral) or Deferoxamine (subcutaneous/IV) are standard.

3. Immune Thrombocytopenia (ITP)

ITP is an acquired, immune-mediated destruction of platelets. In children, it is typically acute, self-limiting, and often follows a viral illness by 1 to 4 weeks.

Clinical Presentation: A previously healthy child suddenly develops petechiae, purpura, and mucosal bleeding (e.g., epistaxis). The patient is otherwise completely well, with no hepatosplenomegaly or lymphadenopathy. Diagnosis: It is a diagnosis of exclusion. Complete blood count reveals isolated thrombocytopenia (often < 20,000/mm³). PT, aPTT, and peripheral smear (other than large platelets) are normal. A bone marrow biopsy is only required if there are atypical features (e.g., unexplained anemia, neutropenia, bone pain, or blasts on smear) to rule out leukemia.

Evidence-Based Management

Management is guided primarily by the severity of bleeding rather than the absolute platelet count.

Observation: Recommended for children with cutaneous manifestations only (petechiae/bruising), regardless of the platelet count. Parents are advised to restrict contact sports and avoid NSAIDs/aspirin.

Pharmacological Therapy: Indicated for patients with mucosal bleeding or severe/life-threatening hemorrhage. First-line options include Corticosteroids, Intravenous Immunoglobulin (IVIG), or Anti-D immune globulin (only for Rh-positive patients with an intact spleen). Platelet transfusions are generally not indicated unless there is life-threatening bleeding (e.g., intracranial hemorrhage), as the transfused platelets will be rapidly destroyed by autoantibodies.